---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-029761"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:56:07.107363+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Incannex reports ~$75M cash, no debt; advances IHL-42X sleep apnea program

## Summary
- Cash position ~$75M, no debt; market cap ~$46M, resulting in negative enterprise value.
- Financing led by healthcare-focused institutional investors funds DReAMzz dose-optimization study for IHL-42X.
- Company expects to start dosing DReAMzz study within months; Phase 2 results showed significant OSA improvements.
- PSX-001 for generalized anxiety disorder progressing with open IND and clinical advisory board.
- Board-approved share buyback program remains available for shareholder value delivery.

## SEC filing metadata
- accession: 0001213900-26-029761
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/0001213900-26-029761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026029761/ea0282288-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-029761
- JSON: https://secwatch.observer/filing/0001213900-26-029761.json
- Plain text: https://secwatch.observer/filing/0001213900-26-029761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.